PURPOSE: The presence of disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients has shown independent prognostic impact. Immunomagnetic enrichment of such cells is an approach to increase the number of detected cells with limited sample volume, especially for circulating tumor cells (CTCs) in blood. The Thomsen-Friedenreich (TF) antigen (CD 176) is a specific oncofetal carbohydrate epitope (Galbeta1-3GalNAcalpha-O) expressed on the surface of various carcinomas. Own studies demonstrated a nearly complete TF expression on DTC-BM, indicating its suitability as marker for immunomagnetic enrichment. METHODS: BM samples of 65 and peripheral blood samples of 11 breast cancer patients were examined immunocytochemically by staining with the anti-Cytokeratin antibody A45-B/B3 before and after immunomagnetic enrichment. Enrichment was done by incubation with the primary antibody TF 2 (IgM), followed by secondary magnetically labelled rat-anti mouse IgM. Cytospin slides were screened manually by bright-field microscopy. RESULTS: 15/65 pts (23%) showed DTC-BM in primary screening with a median of 2/2 mio cells (range 1-10). By enrichment, a median of 23.3 mio cells (0.8-218) could be analysed, increasing positivity to 72% (47/65 pts) with a med. of 4 DTCs (1-105, P < .0001). Blood from 1/11 pts before and 5/11 (45%) after enrichment showed CTCs (med. 2, 1-20), at a med. of 12.4 mio (2.6-38.5) cells analysed. Comparing BM and blood of the same patients after enrichment, 5 were positive in both compartments, 4 showed DTC-BM without presence of CTCs. CONCLUSION: The positive immunomagnetic enrichment technique with TF-antibodies enables to analyse larger sample volumes and increase tumor cell detection rate. This could allow monitoring and characterisation of CTCs as targets for therapies.
PURPOSE: The presence of disseminated tumor cells in the bone marrow (DTC-BM) of breast cancerpatients has shown independent prognostic impact. Immunomagnetic enrichment of such cells is an approach to increase the number of detected cells with limited sample volume, especially for circulating tumor cells (CTCs) in blood. The Thomsen-Friedenreich (TF) antigen (CD 176) is a specific oncofetal carbohydrate epitope (Galbeta1-3GalNAcalpha-O) expressed on the surface of various carcinomas. Own studies demonstrated a nearly complete TF expression on DTC-BM, indicating its suitability as marker for immunomagnetic enrichment. METHODS: BM samples of 65 and peripheral blood samples of 11 breast cancerpatients were examined immunocytochemically by staining with the anti-Cytokeratin antibody A45-B/B3 before and after immunomagnetic enrichment. Enrichment was done by incubation with the primary antibody TF 2 (IgM), followed by secondary magnetically labelled rat-anti mouse IgM. Cytospin slides were screened manually by bright-field microscopy. RESULTS: 15/65 pts (23%) showed DTC-BM in primary screening with a median of 2/2 mio cells (range 1-10). By enrichment, a median of 23.3 mio cells (0.8-218) could be analysed, increasing positivity to 72% (47/65 pts) with a med. of 4 DTCs (1-105, P < .0001). Blood from 1/11 pts before and 5/11 (45%) after enrichment showed CTCs (med. 2, 1-20), at a med. of 12.4 mio (2.6-38.5) cells analysed. Comparing BM and blood of the same patients after enrichment, 5 were positive in both compartments, 4 showed DTC-BM without presence of CTCs. CONCLUSION: The positive immunomagnetic enrichment technique with TF-antibodies enables to analyse larger sample volumes and increase tumor cell detection rate. This could allow monitoring and characterisation of CTCs as targets for therapies.
Authors: B Naume; E Borgen; K Beiske; T K Herstad; G Ravnås; A Renolen; S Trachsel; K Thrane-Steen; S Funderud; G Kvalheim Journal: J Hematother Date: 1997-04
Authors: B Naume; E Borgen; J M Nesland; K Beiske; E Gilen; A Renolen; G Ravnås; H Qvist; R Kåresen; G Kvalheim Journal: Int J Cancer Date: 1998-11-23 Impact factor: 7.396
Authors: Christian Schindlbeck; Udo Jeschke; Sandra Schulze; Uwe Karsten; Wolfgang Janni; Brigitte Rack; Stan Krajewski; Harald Sommer; Klaus Friese Journal: Breast Cancer Res Treat Date: 2006-06-29 Impact factor: 4.872
Authors: W Krüger; C Datta; A Badbaran; F Tögel; K Gutensohn; I Carrero; N Kröger; F Jänicke; A R Zander Journal: Transfusion Date: 2000-12 Impact factor: 3.157
Authors: Daniel F Hayes; Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; M Craig Miller; Jeri Matera; W Jeffrey Allard; Gerald V Doyle; Leon W W M Terstappen Journal: Clin Cancer Res Date: 2006-07-15 Impact factor: 12.531
Authors: Vladislav V Glinsky; Gennadi V Glinsky; Olga V Glinskii; Virginia H Huxley; James R Turk; Valeri V Mossine; Susan L Deutscher; Kenneth J Pienta; Thomas P Quinn Journal: Cancer Res Date: 2003-07-01 Impact factor: 12.701
Authors: Christian Schindlbeck; Ulrich Andergassen; Simone Hofmann; Julia Jückstock; Udo Jeschke; Harald Sommer; Klaus Friese; Wolfgang Janni; Brigitte Rack Journal: J Cancer Res Clin Oncol Date: 2013-03-23 Impact factor: 4.553
Authors: Sreeraj G Pillai; Peixuan Zhu; Chidananda M Siddappa; Daniel L Adams; Shuhong Li; Olga V Makarova; Pete Amstutz; Ryan Nunley; Cha-Mei Tang; Mark A Watson; Rebecca L Aft Journal: PLoS One Date: 2017-01-27 Impact factor: 3.240
Authors: Galatea Kallergi; Sofia Agelaki; Maria A Papadaki; Dimitris Nasias; Alexios Matikas; Dimitris Mavroudis; Vassilis Georgoulias Journal: Breast Cancer Res Date: 2015-08-19 Impact factor: 6.466